LAVA Therapeutics NV financial data

Location
Utrecht
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 684% %
Debt-to-equity 207% %
Return On Equity -108% %
Return On Assets -35% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26,305,295 shares
Common Stock, Shares, Outstanding 26,305,295 shares
Entity Public Float $29,000,000 USD
Common Stock, Value, Issued $3,717,000 USD
Weighted Average Number of Shares Outstanding, Basic 26,899,122 shares 0.2%
Weighted Average Number of Shares Outstanding, Diluted 26,899,122 shares 0.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $6,992,000 USD
Research and Development Expense $19,703,000 USD -73%
General and Administrative Expense $14,641,000 USD 73%
Costs and Expenses $34,344,000 USD -33%
Operating Income (Loss) $29,354,000 USD 33%
Nonoperating Income (Expense) $6,853,000 USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $22,501,000 USD 41%
Income Tax Expense (Benefit) $682,000 USD -94%
Net Income (Loss) Attributable to Parent $23,183,000 USD 42%
Earnings Per Share, Basic 0 USD/shares 41%
Earnings Per Share, Diluted 0 USD/shares 41%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $49,664,000 USD
Other Assets, Current $2,100,000 USD
Assets, Current $51,905,000 USD
Property, Plant and Equipment, Net $43,000 USD
Operating Lease, Right-of-Use Asset $353,000 USD
Other Assets, Noncurrent $10,000 USD
Assets $51,915,000 USD
Accounts Payable, Current $1,698,000 USD
Employee-related Liabilities, Current $1,109,000 USD
Liabilities, Current $4,231,000 USD
Contract with Customer, Liability, Noncurrent $35,000,000 USD
Operating Lease, Liability, Noncurrent $6,000 USD
Liabilities $39,231,000 USD
Accumulated Other Comprehensive Income (Loss), Net of Tax $9,784,000 USD
Retained Earnings (Accumulated Deficit) $194,279,000 USD
Stockholders' Equity Attributable to Parent $12,684,000 USD -62%
Liabilities and Equity $51,915,000 USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $11,645,000 USD -1281%
Net Cash Provided by (Used in) Financing Activities $8,000 USD
Net Cash Provided by (Used in) Investing Activities $15,159,000 USD 2084%
Common Stock, Shares Authorized 90,000,000 shares
Common Stock, Shares, Issued 26,305,295 shares
Common Stock, Par or Stated Value Per Share 0.14 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $49,664,000 USD 84%
Deferred Tax Assets, Valuation Allowance $41,371,000 USD 12%
Deferred Tax Assets, Gross $41,509,000 USD 11%
Operating Lease, Liability $395,000 USD
Payments to Acquire Property, Plant, and Equipment $23,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $22,323,000 USD 28%
Lessee, Operating Lease, Liability, to be Paid $425,000 USD
Property, Plant and Equipment, Gross $3,008,000 USD -9.9%
Operating Lease, Liability, Current $306,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $77,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $343,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.16 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $30,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $3,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $27,967,000 USD 52%
Preferred Stock, Shares Authorized 45,000,000 shares
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,000 USD
Additional Paid in Capital $213,030,000 USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $107,000 USD -26%
Deferred Tax Assets, Net of Valuation Allowance $138,000 USD -37%